Skip to Content

Collaborative drug management agreements between pharmacists employed by community pharmacies and one or more physicians. Pilot program - Conn. Gen. Stat. § 20-631a

Link to the law
This will open in a new window

The Commissioner of Consumer Protection must, after consulting with the Commission of Pharmacy, establish a pilot program that allows a maximum of 10 licensed pharmacists employed by community pharmacies “to enter into [] written protocol-based collaborative drug management agreement[s]” with physicians whereby the pharmacist will manage the drug therapy of “diabetes, asthma, hypertension, hyperlipidemia, osteoporosis, congestive heart failure, or smoking cessation patients. Medicaid beneficiaries may participate in the program.

The collaborative drug therapy management agreement will authorize the pharmacist to, in accordance with a “patient-specific written protocol, “implement, modify or discontinue a drug therapy that has been prescribed for a patient, order associated laboratory tests and administer drugs.”  Each agreement must specify the extent of the pharmacist’s authority and the circumstances requiring the pharmacist to notify the physician. A copy of the protocol and documentation of a pharmacist’s actions must be placed in the patient’s medical record.

Persons cannot use Connecticut’s Freedom of Information Act to obtain information generated or collected during the administration of the pilot program for six months following the generation or collection of the information. Pilot program information is not subject to discovery and is inadmissible as evidence unless the law provides otherwise.


Current as of June 2015